Abvc Biopharma (ABVC) Share-based Compensation (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Share-based Compensation came in at $69171.0 in Q1 2026, up 41.82% YoY from $48773.0 in Q1 2025, and down 97.98% on a QoQ basis from $3.4 million in Q4 2025.
Abvc Biopharma (ABVC) Share-based Compensation (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 14 years of Share-based Compensation data on file, last reported at $69171.0 in Q1 2026.
- Quarterly Share-based Compensation rose 41.82% year-over-year to $69171.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 203.7% YoY) and the FY2025 annual result came in at $4.1 million, up 107.65% from the prior year.
- Share-based Compensation retreated to $69171.0 in Q1 2026, from $3.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.7 million in Q1 2022 to a low of -$3.9 million in Q4 2022.
- A 5-year average of $747837.7 and a median of $254307.5 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1978.5% in 2022, down 15982.25% in 2022.
- Tracing ABVC's Share-based Compensation over 5 years: stood at -$3.9 million in 2022, then surged by 87.0% to -$507009.0 in 2023, then soared by 418.81% to $1.6 million in 2024, then soared by 112.22% to $3.4 million in 2025, then slumped by 97.98% to $69171.0 in 2026.
- The last three Share-based Compensation figures came in at $69171.0 (Q1 2026), $3.4 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Abvc Biopharma | 23.97 Mn | 23.97 Mn | - | 507,041.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 507,041.00 |
| Jun 30, 2026 | 507,041.00 |
| Mar 31, 2026 | 69,171.00 |
| Mar 31, 2026 | 69,171.00 |
| Dec 31, 2025 | 3.43 Mn |
| Dec 31, 2025 | 3.43 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 48,773.00 |
| Mar 31, 2025 | 48,773.00 |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 95,875.00 |
| Sep 30, 2024 | 95,875.00 |
| Jun 30, 2024 | 282,875.00 |
| Jun 30, 2024 | 282,875.00 |
| Mar 31, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.94 Mn |